Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS).
Blauvelt A, Leonardi CL, Gaylis N, Jauch-Lembach J, Balfour A, Lemke L, Hachaichi S, Brueckmann I, Festini T, Wiland P. Blauvelt A, et al. Among authors: jauch lembach j. BioDrugs. 2021 Mar;35(2):229-238. doi: 10.1007/s40259-021-00470-1. Epub 2021 Mar 2. BioDrugs. 2021. PMID: 33651341 Free PMC article. Clinical Trial.
GP2017, an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methods.
von Richter O, Lemke L, Haliduola H, Fuhr R, Koernicke T, Schuck E, Velinova M, Skerjanec A, Poetzl J, Jauch-Lembach J. von Richter O, et al. Among authors: jauch lembach j. Expert Opin Biol Ther. 2019 Oct;19(10):1075-1083. doi: 10.1080/14712598.2019.1571580. Epub 2019 Jan 30. Expert Opin Biol Ther. 2019. PMID: 30698045 Clinical Trial.
Differences in immunogenicity associated with non-product related variability: insights from two pharmacokinetic studies using GP2017, an adalimumab biosimilar.
von Richter O, Lemke L, Haliduola H, Balfour A, Zehnpfennig B, Skerjanec A, Jauch-Lembach J. von Richter O, et al. Among authors: jauch lembach j. Expert Opin Biol Ther. 2019 Oct;19(10):1057-1064. doi: 10.1080/14712598.2019.1603959. Epub 2019 Apr 19. Expert Opin Biol Ther. 2019. PMID: 31002537 Clinical Trial.
Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study.
Wiland P, Jeka S, Dokoupilová E, Brandt-Jürgens J, Miranda Limón JM, Cantalejo Moreira M, Cabello RV, Jauch-Lembach J, Thakur A, Haliduola H, Brueckmann I, Gaylis NB. Wiland P, et al. Among authors: jauch lembach j. BioDrugs. 2020 Dec;34(6):809-823. doi: 10.1007/s40259-020-00447-6. BioDrugs. 2020. PMID: 33119861 Free PMC article. Clinical Trial.
Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody-Positive Primary Membranous Nephropathy.
Rovin BH, Ronco PM, Wetzels JFM, Adler SG, Ayoub I, Zaoui P, Han SH, Dudani JS, Gilbert HN, Patel UD, Manser PT, Jauch-Lembach J, Faulhaber N, Boxhammer R, Härtle S, Sprangers B. Rovin BH, et al. Among authors: jauch lembach j. Kidney Int Rep. 2024 Jun 20;9(9):2635-2647. doi: 10.1016/j.ekir.2024.06.018. eCollection 2024 Sep. Kidney Int Rep. 2024. PMID: 39291206 Free PMC article.